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To conclude, patients with clinical and
biological manifestations suggestive of cryo-
globulins constitute a pitfall for clinicians and
biologists when standard laboratory investi-
gations remain negative for cryoglobulinae-
mia. Unusual in vitro properties of cryo-
globulins, including dependence upon
calcium concentration, should be looked for
in such circumstances.
We thank Ray Langford for reviewing the English
manuscript.
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Computed digital
absorptiometry of the
hand: screening method
of bone loss
in postmenopausal
women with RA
Dual energy x ray absorptiometry (DXA) is
the most commonly used method of measur-
ing bone mineral density (BMD); it has been
shown to be a good predictor of the future
risk of fracture.1Unfortunately, the general-
ised use of DXA is limited as it is expensive
and time consuming, is not portable, and is
available only in specialised clinics.
Computed digital absorptiometry (CDA)
of the hand is a new bone densitometry tech-
nique, designed to assess the BMD of the
middle phalanx of the third finger using a
direct, automated measurement of x ray
attenuation.2This technique is similar to
radiographic absorptiometry but provides
immediate results; in current radiographic
absorptiometry, radiographs are sent to an oV
site processing centre and the results are
received a few days later. CDA is cheap and
quick. Its precision and accuracy seem to be
acceptable, but its ability to discriminate
between patients with osteoporosis and nor-
mal subjects, to predict risk of future fracture,
and to monitor the response to therapeutic
intervention has not been established.
Rheumatoid arthritis (RA) is a risk factor
for osteoporosis.3The available data suggest
that there is an increased risk of hip fracture
in patients with RA, especially when they are
treated with glucocorticoids.4DXA is the pre-
ferred technique for assessing the presence of
bone loss in these patients. However, the
prevalence of RA in the general population is
high, and it is, therefore necessary to use
DXA to investigate only those patients at high
risk of osteoporosis. Criteria to decide who
should be evaluated are currently not avail-
able. Recently, in this journal,5Lems and
Dijkmans presented a proposal from rheuma-
tologists in Amsterdam based on clinical risk
factors.
We have undertaken a study to evaluate
whether CDA might be a useful screening
technique for identifying the patients with RA
who should be examined by DXA. Over a
period of three months all postmenopausal
women with RA, evaluated in the rheumatol-
ogy outpatient clinic, who fulfilled the inclu-
sion criteria were asked to participate. The
inclusion criteria were (a) duration of RA
longer than one year, (b) duration of
postmenopausal period longer than one year,
and (c) no current treatment with bone thin-
ning agents.
Forty five patients fulfilled the inclusion
criteria and consent was obtained from 40 of
these. In these patients BMD was assessed by
DXA and CDA on the same day. One further
patient was not be included in the study as
she had a severe ulnar deviation that did not
allow CDA to be used.
For DXA, BMD (g/cm2) of the lumbar
spine and upper femur was assessed using a
dual energy x ray system (Hologic QDR
1000, Hologic Inc, Waltham, Mass); we con-
sidered the mean value of the L2–4 vertebrae
and the value of the femoral neck. For CDA,
BMD (g/cm2) of the middle phalanx of the
third finger of the non-dominant hand was
assessed using a dual energy x ray system
(AccuDEXA, Schick Technologies, Long
Island, NY). The x ray attenuation data were
automatically processed and represented as a
grey scale image. To assess the in vivo short
term precision, 10 serial measurements (with
interim repositioning) were performed in
seven healthy volunteers. The in vivo preci-
sion of AccuDEXA, expressed as a coeYcient
of variation, was 1.16% (0.74 to 1.56). Data
were cross referenced with the T score.
According to WHO criteria,1osteoporosis is
defined as a T score below −2.5 .
A Spearman correlation test and linear
regression analysis were used to test the rela-
tion between the variables; p<0.05 was
considered significant. A 2×2 table was used
to evaluate the positive and negative predic-
tive value of CDA for the diagnosis of
osteoporosis established by DXA.
Table 1 lists the clinical characteristics of
the patients and the mean BMD values
obtained.
BMD at the lumbar spine and at the non-
dominant hand correlated significantly (r =
0.51, p<0.01). Similarly, BMD at the femoral
neck and at the non-dominant hand were sig-
nificantly correlated (r = 0.51, p<0.01).
DXA showed that 13 patients had oste-
oporosis and CDA that 16 patients had the
disease in at least one of the evaluated zones.
The positive predictive value of CDA for the
diagnosis of osteoporosis was 56%. The
negative predictive value for the diagnosis of
osteoporosis was 83%.
The correlations found between BMD at
the non-dominant hand and BMD at the
lumbar spine and femoral neck were moder-
ate. A negative predictive value was consid-
ered acceptable. Our results suggest that
CDA could be a screening method used to
decide which patients with RA should be
investigated for osteoporosis. Further investi-
gations are needed to confirm our findings.
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Table 1 Clinical characteristics of the patients with RA and BMD values obtained (n=39). Values
are expressed as mean (SD)
Age (y) 61.2 (8.3)
Duration of postmenopausal period (y) 13.3 (7.5)
Duration of rheumatoid arthritis (y) 9.7 (6.4)
Rheumatoid factor positive (n) 30
Erosive RA (n) 16
Treatment with low dose glucocorticoids (n) 32
BMD* at the lumbar spine (g/cm2) 0.840 (0.150)
BMD at the femoral neck (g/cm2) 0.660 (0.110)
BMD at the middle phalanx of the third finger (g/cm2) 0.390 (0.090)
*BMD = bone mineral density.
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